Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC Ltd : World’s leading Event Organizer

Conference Series LLC Ltd Conferences gaining more Readers and Visitors

Conference Series LLC Ltd Web Metrics at a Glance

  • 3000+ Global Events
  • 25 Million+ Visitors
  • 25000+ unique visitors per conference
  • 70000+ page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Parkinsons 2019

About Conference


Conference Series LLC LTD proudly presents International Conference on Parkinson’s and Neurodegenerative diseases. We invite participants around the world to Dubai, UAE for Parkinson's 2020 held during December 30-31, 2019.

Parkinson's deals with Neurological Syndromes caused due to leakage of electric impulse in neurons which leads to loss of communication. This kind of medical conditions are getting frequent in humans at present situations. It has been observed there are number of diseases associated with Neurological disorders for examples Parkinson’s diseasesHuntington’sAlzheimer’s diseasebrain tumours, Multiple SclerosisSpinal Muscular Atrophy, Brain StrokeEpilepsyAmyotrophic Lateral Sclerosis.

According to current survey Neurological disorders occupy first place in Europe Brain disorders are like Brain Tumour, Cerebral palsychiari malformationCraniofacial abnormalitiesCraniosynostosisDevelopmental disordersEncephalopathyEpilepsy are recognized by World Health Organization in Europe. It is been identified 1.2 million people in Europe are suffering with Parkinson’s approximately 260000 people in Germany, 200000 people in Italy, 150000 people in Spain, 120000 people in UK, 117000 people in France are suffering from Parkinson's disease.

World Health Organization (WHO) and World Federation of Neurology (WFN) were collaborated after find the rate of Neurological disorders worldwide. An international Survey of Country Resources for Neurological disorders effects 109 countries and covering over 90% of the world’s population. This survey helps to collect valuable information regarding aspects of neurological care all around the world.  

 At National Institute of Health funding package is of $34 billion for the economic year 2017 to improve life of patients who are suffering from Parkinson’s disease and to raise the awareness on Neurological disorders around the World. PRP (Parkinson's Research Program) fund received amount of $16 million annually to research in neuromuscular disorders such as Alzheimer’s, Parkinson’s disease & Huntington’s disease.

 

Why to attend?

International Conference on Parkinson’s and Neurodegenerative diseases provides best plat form for Neurologists, Neurosurgeons, Scientists, Clinical Industry Specialists, Neurology Experts, Young Researchers with an aim to make patients feel better with innovative research outcomes.

Target audience:

Neuro physicians, Neruo surgeons, Neurologists, Psychiatrist, Physiotherapists, Neruo Specialists, Researchers, Professors, Industrials Experts, Nutritional Scientists, Lecturers and Students from Academic study in Parkinson’s and Huntington’s diseases , Pharma researchers on Neurology and Neuroscience, Therapists and Diagnostic Experts.

Market Analysis

On behalf of our Organizing committee members we welcome attendees like Speakers, Exhibitors, delegates, Poster presenters, Students, Young researchers from across the world to unleash the innovative ideas in the field of neuroscience and brain disorders at Parkinson’s congress 2019 held during 02-03, December 2019

This Parkinson's International conference of Europe focus on innovative ideas of Parkinson’s and Huntington’s diseases treatment and research

Reasons to undertake:

Parkinson's congress receive great response and support from worldwide NeuroResearchers. We Hope to make Parkinson's congress 2019 a grand success with the support of highly eminent speakers from Neuroscience and Parkinson’s disease communities. We promise our speakers world class hotel facilities and hospitality along with updated research knowledge on Parkinson’s and other neurological disorders.

According to World Health Organization (WHO) and World Federation of Neurology survey 6.3 million people are suffering with Parkinson's disease. The age is usually over 60 but it is estimated that one in tem are diagnosed before the age of 50 and it can affect people in their 40’s and younger Especially in Europe Parkinson’s disease is diagnosed 1 per 1000 people making it second most common neurodegenerative disorder.

As per the Neurological research till date with was clear that dopamine a neurotransmitter in brain gradually fall its level. Which leads to Parkinson’s disease it was observed that dopamine – generating cells known as dopaminergic neurons in the substantia nigra part of brain have died. Research say a male has 50% higher risk of developing Parkinson’s disease than a female, This progressive nervous system disorder affects the persons movement like speak, write and other voluntary movements different treatments for Parkinson’s disease were used but still death rate of Parkinson’s disease was gradually increasing. Approximately one million adults in USA are living with Parkinson’s disease and 60000 are diagnosed yearly and In United Kingdom 127000 people have Parkinson’s disease

About UAE:

Dubai is the largest and most populous city in the United Arab Emirates. On the southeast coast of the Persian Gulf, it is the capital of the Emirate of Dubai, one of the seven emirates that make up the country. Dubai is a global city and is a major business and transport hub of the Middle East. Dubai is situated on the Persian Gulf coast of the United Arab Emirates and is roughly at sea level. The emirate of Dubai shares borders with Abu Dhabi in the south, Sharjah in the northeast, and the Sultanate of Oman in the southeastDubai lies directly within the Arabian Desert. However, the topography of Dubai is significantly different from that of the southern portion of the UAE.

Dubai Tourism is an important part of the Dubai government's strategy to maintain the flow of foreign cash into the emirate. Dubai has been called the "shopping capital of the Middle East. Dubai alone has more than 70 shopping centres, including the world's largest shopping centre. Dubai mall. Dubai has a rich collection of buildings and structures of various architectural styles. Many modern interpretations of Islamic architecture can be found here, due to a boom in construction and architectural innovation in the Arab World in general, and in Dubai in particular, supported not only by top Arab or international architectural and engineering design firms such as Al Hashemi and Aedas but also by top firms of New York and Chicago. The most recent addition to the magnificent skyline of Dubai is the 150 meter high Dubai frame, located in Zabeel Park, Dubai.

Major Associations around the globe:

National Parkinson Foundation

American Parkinson Disease Association (APDA)

Parkinson’s disease Foundation

Movement Disorder Society of Australia

Parkinson's Unity Walk

Movement Disorder Society of Japan

Moroccan Neurological Society Movement Disorders Group

Italian Society for the Study of Parkinson Disease, Extrapyramidal Diseases and Dementia

Ecuador Movement Disorders Group

Austrian Parkinson's disease Society

Danish Movement Disorder Society

International Parkinson and Movement Disorder Society

Parkinson’s disease and Movement Disorders Society of India

Top universities globally working in the field of Parkinson Disease

University of Bath

The University of Queensland

University of Bristol

University of Cambridge

The Imperial College of Science and Medicine

Duke University

University of Milan

Karolinska Institute

University of Hamburg

The University of Edinburgh

University of Munich

University of Rochester

University of Zurich

Leiden University

University of Bristol

University of Helsinki

University of Freiburg

University of Frankfurt

Top universities in Austria:

Medical University of Vienna

Medical University of Innsbruck

Medical University of Graz

University of Vienna

Paracelsus Private Medical University

 

Sessions

Sessions

Session 1Parkinson Disease

Parkinson’s disease (PD) is a chronic and progressive disease of nervous system that possesses symptoms which continue and become worse over time. It is the second commonest neurodegenerative disease after Alzheimer's disease, and in the UK, has a lifetime prevalence of between 0.1 and 0.3% of the population. The basic reason behind this condition is malfunction and death of vital nerve cells in brain. In normal conditions nerve cells present in the brain produces a neurotransmitter called dopamine that is responsible for signalling movement, emotions and co-ordination but in the case of diseased individual dopamine production slows down, hence the individual become unable to control the movement normally. There is no cure but treatment involves medication and surgery. Slowness of voluntary movements, reduced facial appearance, repetitious tongue, and diminished eye flashing, A shuffling gait with deprived arm swing and curved posture, Shaky stability; difficulty rising from a sitting position, Swallowing problems in later stages.

Related Conferences:

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session 2Huntington’s disease

Huntington’s disease is inherited from Parents and often symptoms will be more like Parkinson’s disease which include problem with mood, mental abilities, Swallowing, Speaking, Sleep Disturbances followed by loss of co-ordination and unsteady gait. A gene called HTT (Huntingtin) which is responsible for coding protein Huntingtin, if any mutation to that gene it will cause disturbances in the brain and results in death of brain cell and leads to Huntington’s disease. Abnormalities with the mutant huntingtin include Cardiac Failure, Weight Loss, Osteoporosis, reduced glucose level. This condition is normally observed in the individuals under the age of fifties.

Related Conferences:

13th Annual Conference on Dementia and Alzheimer’s Disease, December 13-15, 2018 Abu Dhabi, UAE; World Brain Congress, December 5-7, 2018 Dubai, UAE; 13th International Conference on Neurology and Brain Disorders, November 15-16, 2018 Osaka, Japan; World Neuron Congress, November 19-21, 2018 Bucharest, Romania; 5th World Parkinson Congress, June 4-7 2019

Session 3Risk Factors of Parkinson’s disease

Symptoms and progression of disease will not be similar among the suffering individuals but people with Parkinson’s are at higher rate of developing related risks. Developing these conditions is not a certainty, only a possibility. Knowing the conditions can help a person with Parkinson’s disease or associated symptoms and helps to take preventative measures for a better life. Parkinson’s disease has a chance of creating mental ailment which can be mild or serious. It includes cognition (early stage symptoms), mood, and behaviour which are considered as major impairment when compared to normal population. The common mood alterations seen in the patients are despair, eagerness, indifference.

Related Conferences:  

5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neuro-genetics Conference, November 19-20, 2019 in Istanbul, Turkey

Session 4: Diagnosis for Parkinson’s disease

Early stage identification of Parkinson’s disease is difficult but includes some imaging studies. MRI (magnetic resonance imaging) and CT (computer tomogram) are used by many physicians to find out other relating Parkinson’s diseases such as encephalitis, Tumours, Hydrocephalus. Level of dopamine release and activity of brain can easily detect using PET and SPECT examining.

Related Conferences:

Related Conferences:  

5th International Conference on Epilepsy & Treatment  on August 19-20, 2019 at Vienna, Austria, 3rd International Congress on Addictive Behaviour & Dual Diagnosis on September 05-06, 2019 at Budapest, Hungary,  International Conference on Public Mental Health and Neuroscience held amid September 23-24, 2019 in Abu Dhabi, UAE, 32nd Clinical Neuroscience and Neuro-genetics Conference, November 19-20, 2019 in Istanbul, Turkey

Session 5Parkinson’s disease: Complications

Parkinson's disease is usually accompanied by additional problems, which may be cured and they are thinking difficulties, swallowing problems, depression and emotional changes, sleep difficulties, constipation, blood pressure changes, fatigue, pain.

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session 6Insights and therapeuticsParkinson’s disease

No cure has been identified to Parkinson’s disease, but use of drugs can slow down the progression. Normally prescribed by physicians include change of life style, regular aerobic exercise and prescribed therapeutic supplement. It is noted that people will have beneficial effect who are taking co-enzyme Q10 during their initial stage of disease. It is unclear how genetically changes cause Parkinson disease or influence the risk of developing the disorder. Some gene mutations (alterations) such as LRRK 2, PARK 7, PINK 1, PRKN disturb the cell mechanism that breaks down undesired proteins in neurons which are responsible for dopamine production. Hence, under graded proteins accumulate, resulting in death of vital nerve cells and subsequently lowers the level of dopamine production. In most cases of Parkinson disease, protein deposits called Lewy bodies. It is unclear whether Lewy bodies play a key role in killing nerve cells or just part of the cells which are responsible to the disease. Yoga, massage, acupuncture, meditation, music or art therapy, alexander technique is also regarding as best methods to control neurological disorders particularly Parkinson’s disease, Alzheimer’s and neuropsychiatric. Tetra Benzamine, neuroleptics, mirtazapine can be taken to for treating chorea.

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session 7: Neurosurgery

Presently Deep brain stimulation is widely recommended for improving people suffering with Parkinson’s disease one is deep brain stimulation (DBS) and is performed by inserting a tube in the small intestine and is used to treat a variety of deactivating neurological symptoms most commonly the draining symptoms of Parkinson’s disease (PD), such as tremor, rigidity, stiffness, slowed movement, and walking problems. There will be no effect with using DBS to healthy brain tissue by terminating nerve cells. Instead the procedure blocks electrical signals from targeted areas in the brain.

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session 8:  Epidemiology of Parkinson’s

Parkinson's disease is a neurodegenerative disorder and the cause of it remained a mystery to the scientific community. Researchers say by exposing to harmful chemicals and Pesticides mutations occurs in the genes and results in neurological disorders. With age, the condition of disease increases exponentially and men are in higher proportion to prone compared to women. On an average 10million individuals are found to be suffering from Parkinson’s disease, from where only four present of people with Parkinson’s disease are diagnosed before the age of 50. An estimated of 40% to 60% of Parkinson disease patients suffering from depression. United States stands in the fourth position in considering the death of people due to Parkinson’s disease.

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session on 9Clinical Trials in Parkinson’s diseases

To develop a promising drug or treatment for Parkinson’s disease observational study is being conducted by scientist in laboratory to provide patients with better life. Clinical trials are performed to slowdown the progression and reduce the symptoms.

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session 10: Psychology of Parkinson's Patients 

Parkinson's disease is frequently associated with Psychological disorders like psychotic disorders, depression, psychotic disorders, and dementia after examination of psychological disorders in Parkinson’s disease one-third of Parkinson's patients experience visual hallucinations. Mood disorder and depressive symptoms are common in Parkinson's patients.

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

Session on 11: Chemotherapy for Parkinson's Psychological disorders

It is clear that Parkinson's disease is associated with psychological disorders which can be treated with Chemotherapy (drugs) but according to clinical trials drugs for psychological disorders can give side effect on patient so it is vital to know about the therapist drug used for Parkinson's psychological disorders. Dose reduction of certain drugs sometimes improve psychotic disorders, Clozapine is effective and does not worse Parkinson’s symptoms 

Related Conferences:  

11th International Conference on Vascular dementia Feb 15-16, 2019 at Amsterdam, Netherlands,  28th World Conference on Neurology and Therapeutics February 28 - March 02, 2019 in Berlin, Germany,  Annual Congress on Neurology and Neuroscience March 14-15, 2019 at Paris, France, 8th International Conference on Brain Injury and Neurological Disorders March 14-15, 2019 in Paris, France, 24th International Conference on Neurosurgery and Neuroscience, March 18-20, 2019 Edinburgh, Scotland, 23rd International Conference on Neurology and Neurophysiology, March 18-19, 2019 in Edinburgh, Scotland,  5th World Parkinson Congress, June 4-7 2019

 

To Collaborate Scientific Professionals around the World

Conference Date December 02-03, 2019

Speaker Opportunity

Day 1 Day 2

Supported By

Journal of Alzheimers Disease & Parkinsonism Journal of Neurological Disorders Journal of Neurology & Neurophysiology

All accepted abstracts will be published in respective Conference Series LLC LTD International Journals.

Abstracts will be provided with Digital Object Identifier by